文献速递妇科产科

HIV阳性女性的妇科癌症:系统综述与Meta分析

Gynecologic cancer in HIV-positive women: a systematic review and meta-analysis.
PubMed 文献 · Am J Obstet Gynecol · 2019-02-13

该系统综述与Meta分析检索2000年至2017年5月1日的文献,纳入58项研究、292202例HIV感染女性及528例HIV感染合并妇科癌症女性,计算子宫内膜癌、卵巢癌和外阴阴道癌的标准化发病率,并汇总肿瘤分期与治疗结局。结果显示卵巢癌和外阴阴道癌发病率高于一般人群,子宫内膜癌发病率与一般人群相似,但非艾滋病定义妇科癌症的治疗与结局数据匮乏。

要点

  • HIV阳性女性卵巢癌和外阴阴道癌发病率高于一般人群,子宫内膜癌发病率与一般人群相似。
  • 纳入研究中仅3、4、20篇分别关注子宫内膜癌、卵巢癌和外阴阴道癌的治疗与结局。
  • 57%的HIV阳性妇科癌症女性在早期确诊,且全部接受了癌症治疗。

核心结论

  • HIV感染女性中卵巢癌和外阴阴道癌发病率高于一般人群,子宫内膜癌发病率与一般人群相似。
  • 非艾滋病定义妇科癌症的治疗与结局数据匮乏。
  • 鉴于妇科癌症发病率升高,针对该人群的专门研究对改善HIV阳性女性的治疗和结局至关重要。

研究设计与样本

  • 系统综述与Meta分析,检索MEDLINE、EMBASE、ClinicalTrials.gov和Cochrane对照试验中心注册库中2000年至2017年5月1日发表的英文研究,方案注册号为PROSPERO-CRD42017064525。
  • 纳入包含1例及以上HIV阳性子宫内膜癌、卵巢癌或外阴阴道癌女性并报告发病率、治疗方案或生存的研究。
  • 共筛选5744篇摘要,最终纳入70篇文章、58项研究,涉及292202例HIV感染女性和528例HIV感染合并妇科癌症女性。
  • 发病率合并估计采用随机效应模型,肿瘤分期和结局的合并估计由病例研究平均得出。

主要发现

  • 子宫内膜癌标准化发病比为4.38(95%CI 0.26-8.49)。
  • 卵巢癌标准化发病比为3.21(95%CI 2.29-4.13)。
  • 外阴阴道癌标准化发病比为21.93(95%CI 13.50-30.35)。
  • 57%的女性在早期确诊,且全部接受了癌症治疗。
  • 53%的文章关注发病率,仅3、4、20篇文章分别关注子宫内膜癌、卵巢癌和外阴阴道癌的治疗与结局。

局限性

  • 非艾滋病定义妇科癌症的治疗与结局数据匮乏。
  • 仅3、4、20篇文章分别关注子宫内膜癌、卵巢癌和外阴阴道癌的治疗与结局。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: While there is a significant body of literature on cervical cancer in HIV-positive women, little is known about other gynecologic cancers in this population. OBJECTIVE: The objective of this systematic review and meta-analysis is to describe the incidence, presentation, treatment, and outcomes for HIV-positive women with non-acquired immunodeficiency syndrome-defining gynecologic cancers. STUDY DESIGN: We searched MEDLINE, EMBASE, ClinicalTrials.gov, and the Cochrane Central Register of Controlled Trials for English-language studies published from 2000 to May 1, 2017. Studies containing 1 or more HIV-positive women with endometrial, ovarian, or vulvovaginal cancer and reporting incidence, treatment regimen, or survival were included. Two authors independently reviewed abstracts and full-text articles for inclusion and assessed study quality (details of the review protocol were registered as PROSPERO-CRD42017064525). Pooled estimates of incidence were calculated using random-effects models. Pooled estimates of cancer presentation and outcomes were averaged from case studies. RESULTS: Of 5744 abstracts screened, we identified 70 articles on 58 studies on 292,202 women with HIV and 528 women with HIV and gynecologic cancer for inclusion. Most articles (53%) focused on incidence, and only 3, 4, and 20 articles focused on treatment and outcomes of endometrial, ovarian, and vulvovaginal cancers, respectively. The standardized incidence ratios for endometrial, ovarian, and vulvovaginal cancers were 4.38 (95% confidence interval 0.26-8.49) for endometrial cancer, 3.21 (95% confidence interval 2.29-4.13) for ovarian cancer, and 21.93 (95% confidence interval 13.50-30.35) for vulvovaginal cancer. Fifty-seven percent of women were diagnosed at an early stage, and all received cancer treatment. CONCLUSION: In women with HIV, the incidence of ovarian and vulvovaginal cancer were higher than the general population, while incidence of endometrial cancer was similar. However, there was a paucity of data on treatment and outcomes for non-acquired immunodeficiency syndrome-defining gynecologic cancers. Given the increased incidence of gynecologic cancer, specific research on this population is essential to improve treatment and outcomes for HIV-positive women.

来源:Am J Obstet Gynecol,查看原文。版权归原作者所有。

引用

  1. Smith AJB, Varma S, Rositch AF, et al. Gynecologic cancer in HIV-positive women: a systematic review and meta-analysis. Am J Obstet Gynecol. 2019. PMID: 30771344. doi:10.1016/j.ajog.2019.02.022

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。